CRISPR Therapeutics AG
CRSP
$56.75
-$3.25-5.42%
NASDAQ
| 12/31/2025 | 09/30/2025 | 06/30/2025 | 03/31/2025 | 12/31/2024 | |
|---|---|---|---|---|---|
| Net Income | -130.61M | -106.44M | -208.55M | -136.00M | -37.31M |
| Total Depreciation and Amortization | 5.66M | 4.43M | 4.65M | 4.74M | 4.84M |
| Total Amortization of Deferred Charges | -- | -- | -- | -- | -- |
| Total Other Non-Cash Items | 9.76M | 6.47M | 106.53M | 22.47M | 6.79M |
| Change in Net Operating Assets | 22.64M | 10.91M | -16.51M | 54.85M | -24.35M |
| Cash from Operations | -92.55M | -84.63M | -113.88M | -53.95M | -50.03M |
| Capital Expenditure | -517.00K | -74.00K | -117.00K | -206.00K | -254.00K |
| Sale of Property, Plant, and Equipment | -- | -- | -- | -- | -- |
| Cash Acquisitions | -- | -- | -- | -- | -- |
| Divestitures | -- | -- | -- | -- | -- |
| Other Investing Activities | 37.72M | -119.15M | 70.09M | -19.55M | 106.08M |
| Cash from Investing | 37.20M | -119.23M | 69.98M | -19.76M | 105.83M |
| Total Debt Issued | -- | -- | -- | -- | -- |
| Total Debt Repaid | -- | -- | -- | -- | -- |
| Issuance of Common Stock | 116.41M | 296.77M | 2.26M | 10.59M | 16.88M |
| Repurchase of Common Stock | -- | -- | -- | -- | -- |
| Issuance of Preferred Stock | -- | -- | -- | -- | -- |
| Repurchase of Preferred Stock | -- | -- | -- | -- | -- |
| Total Dividends Paid | -- | -- | -- | -- | -- |
| Other Financing Activities | -- | -- | -- | -- | -- |
| Cash from Financing | 116.41M | 296.77M | 2.26M | 10.59M | 16.88M |
| Foreign Exchange rate Adjustments | 1.00K | -27.00K | 80.00K | 41.00K | -87.00K |
| Miscellaneous Cash Flow Adjustments | -- | -- | -- | -- | -- |
| Net Change in Cash | 61.06M | 92.88M | -41.57M | -63.07M | 72.59M |